Sanofi (SNY) 6-K Sanofi delivers Business EPS(1) growth of 10.3% at CER in Q3 2014

Exhibit 99.8

PRODUCT SALES STATEMENT, FOR THE PRODUCT SALES MEASURING PERIOD ENDED SEPTEMBER 30, 2014

As called for under §5.4 of the Contingent Value Rights Agreement by and between Sanofi (formerly known as sanofi-aventis) and American Stock Transfer & Trust Company LLC dated as of March 30, 2011.  All capitalized terms used in the present Product Sales Statement have the respective meanings ascribed to them therein. Amounts set forth herein are not necessarily indicative of results that will be achieved in subsequent Product Sales Measuring Periods.

Sales data to be provided prior to fulfilment of Product Sales Milestone #1:

For the Product

	Q3 2014			Q2 2014			Q1 2014			Q4 2013
Market	(I)	(II)	X- rate	(I)	(II)	X- rate	(I)	(II)	X- rate	(I)	(II)	X- rate
Major Markets
USA				0	0		0	0		0	0
UK	0.9	0.8	0.599	0	0		0	0		0	0
France				0	0		0	0		0	0
Germany	4.8	4.4	0.755	6.1	5.7	0.729	4.7	4.3	0.730	2.0	1.7	0.735
Italy				0	0		0	0		0	0
Spain				0	0		0	0		0	0
Subtotal	5.7	5.2		6.1	5.7		4.7	4.3		2.0	1.7
All other…	4.5	4.4	Misc.	2.9	2.7	Misc.	2.3	2.2	Misc.	0.7	0.6	Misc.
Exclusions
Oncology(1)	0	0		0	0		0	0		0	0
Transplant Indications*	**	**		1.1(2)	N/A		1.2	N/A		1.3	N/A

Legend:

(I):	Aggregate gross amount invoiced by the Company, its Affiliates and its licensees for sales of the Product by the Company, its Affiliates and licensees of the Company and its Affiliates to third parties, in millions of United States dollars.
(II):	Product Sales, in millions of United States dollars.
X-rate:	Exchange rates used for conversion of the specified Major Market’s foreign currency into United States dollars for the quarter indicated. Exchange rates for other markets will be provided to the extent there are sales invoiced in currencies other than the United States dollar.
*:	Note that amounts appearing in this line are a subset of the amounts appearing in the “Oncology” line, above, provided for information purposes and calculated by reference to relevant data compiled by the UNOS (United Network for Organ Sharing).
**:	During the period under review, there were no Transplant Indication stock keeping units (SKUs) recorded. UNOS data specifying Transplant Indication usage for the specified period is not available as of the date of this Statement.
N/A:	Not applicable.
(1):	The Company is in the process of ceasing the commercialization of Campath® on a global basis. In the countries where the sales have ceased, Campath® is being made available to patients at no cost through a patient access/distribution program. Previously sold product amounting to 0.3 million of United States dollars were returned to the Company during the quarter.
(2):	Preliminary figure.

Do Product Sales in the Product Sales Measuring Period ended September 30, 2014 include Product Sales of a Combination Product? x No  o Yes

Has any Product Sales Milestone been achieved during the Product Sales Measuring Period ended September 30, 2014? x No o Yes

After due inquiry and to the best of the knowledge and belief of the undersigned, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Sanofi
By:	/s/ Jérôme Contamine
Name:	Jérôme Contamine
Title:	Executive Vice President, Chief Financial Officer
Date:	October 28, 2014